



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Haoyu Sun
✉ haoyusun@ustc.edu.cn
Zhigang Tian
✉ tzg@ustc.edu.cn

RECEIVED 03 January 2024
ACCEPTED 05 January 2024
PUBLISHED 16 January 2024

CITATION

Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, Tian Z and Sun H (2024) Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Front. Immunol. 15:1365027.
doi: 10.3389/fimmu.2024.1365027

COPYRIGHT

© 2024 Xiao, Cheng, Zheng, Fang, Zhang, Sun, Tian and Sun. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

Xinghui Xiao^{1,2}, Ying Cheng^{1,2}, Xiaodong Zheng^{1,2},
Yuhang Fang^{1,2}, Yu Zhang^{1,2}, Rui Sun^{1,2}, Zhigang Tian^{1,2,3*}
and Haoyu Sun^{1,2*}

¹Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, ²Institute of Immunology, University of Science and Technology of China, Hefei, China, ³Hefei TG ImmunoPharma Corporation Limited, Hefei, China

KEYWORDS

NK-cell engager, T-cell engager, tumor immunotherapy, antitumor, proinflammatory cytokines

A Corrigendum on

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

By Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, Tian Z and Sun H (2023) *Front. Immunol.* 14:1113303. doi: 10.3389/fimmu.2023.1113303

In the published article, there was an error in the funding statement for the National Key R&D Program of China (2019YFA0508502/3, 2018YFA0507403); Natural Science Foundation of China (8222053, 81972679); Natural Science Foundation of Anhui Province (2008085MH252). The correct Funding statement appears below.

Funding

This work was supported by the National Key R&D Program of China (2019YFA0508502/3, 2018YFA0507403); Natural Science Foundation of China (8222053, 81972679); Natural Science Foundation of Anhui Province (2008085MH252).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.